Ethiopia has taken a deliberate step toward becoming one of the few African countries whose medical device oversight meets internationally recognised standards, running a week-long, WHO-assisted self-assessment of its regulatory system from 27 to 31 July. The exercise, led by the Ethiopian Food and Drug Authority (EFDA), measured the country’s capacity to regulate everything from diagnostic tests to surgical equipment against the World Health Organization’s Global Benchmarking Tool Plus Medical Devices, a framework built on more than 250 indicators.
What makes this Ethiopia medical device regulation push notable is not the exercise itself but the track record behind it. A year earlier, Ethiopia became the ninth African country — and the first in the Intergovernmental Authority on Development (IGAD) region — to reach WHO Maturity Level 3 for medicines and vaccine regulation, joining Egypt, Ghana, Nigeria, South Africa, Tanzania, Zimbabwe, Senegal and Rwanda. ML3 status signals a stable, well-functioning, integrated regulatory system capable of reliably authorising products, monitoring safety and conducting market surveillance — the kind of designation that international manufacturers and donors treat as a baseline of trust. EFDA Director General Heran Gerba has been explicit that the institutional muscle built reaching that milestone is now being redirected at medical devices, a far more technically demanding category that spans everything from thermometers to imaging equipment and in vitro diagnostics.
The self-benchmarking exercise itself was deliberately modest in scope: seven regulatory functions were assessed, from registration and post-market surveillance to licensing of establishments and clinical trial oversight, with EFDA staff conducting the evaluation while WHO technical officers verified the findings rather than independently scoring them. That distinction matters. Assisted self-benchmarking is preparatory groundwork, not the formal WHO assessment that ultimately confers a maturity level — the outcome here was an updated Institutional Development Plan and a roadmap toward that later, independent evaluation, rather than a designation Ethiopia can claim today.
Still, the stakes attached to eventually reaching that designation for medical devices are considerable, and they extend well beyond Ethiopia’s own health system. The World Bank has documented that Ethiopia’s ML3 status for medicines already accounts for more than 40 percent of the domestic medicine supply now coming from local manufacturers, up from a market that was almost entirely import-dependent, with the Kilinto Special Economic Zone in Addis Ababa purpose-built to house that growing production base. A comparable maturity level for medical devices would extend the same logic to a category of products Ethiopia currently imports almost entirely, opening a path for domestic manufacturers to eventually produce and export devices rather than relying on foreign suppliers — a meaningful shift for a country of over 130 million people whose health system, like much of the continent’s, has historically depended on imported diagnostic and treatment equipment.
That ambition sits inside a broader continental push to fix a longstanding weakness in African health governance: fragmented, duplicative regulatory systems that slow down access to safe products and discourage investment in local manufacturing. The World Health Organization and the African Medicines Agency signed a framework agreement in May 2026 explicitly aimed at reducing that fragmentation, building shared regulatory capacity across the continent and supporting local production during public health emergencies — the same institutional logic driving Ethiopia’s own benchmarking exercise, just scaled up to 55 member states. For African governments watching from outside Ethiopia, that overlap is instructive: national regulatory strengthening and continental harmonisation are increasingly treated as two sides of the same project, not competing priorities.
The practical payoff of stronger medical device regulation touches several audiences at once. For African patients, it means greater assurance that diagnostic tests and treatment devices in circulation have actually been vetted rather than simply imported and distributed. For regional manufacturers and investors, a credible regulator lowers the cost of entering the Ethiopian market and, eventually, of exporting Ethiopian-made devices into neighbouring economies under frameworks like the African Continental Free Trade Area. And for health workers on the ground — the people ultimately handling this equipment — it means fewer substandard or poorly calibrated devices making their way into clinics and hospitals in the first place. EFDA’s own account of the exercise quoted Heran Gerba describing the process as building directly on the lessons and institutional capacity gained through the medicines benchmarking a year earlier, a signal that Ethiopia is treating this as a sustained programme rather than a one-off exercise.
What happens next is a formal WHO benchmarking process, informed by the roadmap EFDA and WHO agreed during the July assessment — the step that would actually confer a maturity level for medical devices rather than simply preparing for one. Given how long Ethiopia’s medicines benchmarking took to translate into tangible manufacturing growth, that formal process and its aftermath are likely to unfold over a period of years rather than months. For a continent where regulatory capacity remains one of the more persistent bottlenecks to expanding local production of essential health products, Ethiopia’s progress — and how quickly it converts self-assessment into an internationally recognised designation — will be worth watching as a marker of what African-led health regulation can achieve when it builds deliberately, one product category at a time.
